IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to Generic Atelvia® Delayed-Release Tablets, 35 mg
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Atelvia® (Risedronate sodium) delayed-release tablets, 35 mg.
Help employers find you! Check out all the jobs and post your resume.